Here’s why Zip shares had a 10% dead cat bounce on Tuesday
Zip shares had a 10% dead cat bounce on Tuesday. For those who are unaware, a dead cat bounce is a small, brief recovery in the price of a declining stock. Despite the gain today, they are down nearly half in the last year and down 97% from all time highs.
Zip (ASX:ZIP) share price chart, log scale (Source: TradingView)
Why Zip shares had a dead cat bounce
Zip released its results for the September quarter (1Q24) this morning and some investors seemed to like it. The company boasted that it recorded positive cash EBITDA for the period. It recorded 32% revenue growth to $204.4m, 11% transaction volume growth to $2.3bn and it boasted 6.1m active customers.
The company told investors US bad debts were below its target range and that it had signed several key merchants during the quarter including Amaysim, and R.M. Williams. And finally, it claimed to have a health balance sheet with the face value of its Convertible Notes reducing to $110.1m.
So back to $12 per share?
We wouldn’t think so. Afterpay was, and still is, a great company. But too many investors have sought to find another one like it and bought several other companies that have done very little in comparison to Afterpay (if anything).
There were some negative signs such as a decline in transactions and transaction volume in the ANZ market – 6.1% quarter-on-quarter and 9.6% year-on-year – as well as a fall in Active Customers across the globe. And even though bad debts are lower than a year ago, they rose from 1.84% to 1.99% in the past quarter. And this is not the first dead cat bounce we have seen out of this company either. Investors betting that it will return to 2021 highs (or perhaps even 2022 highs) should expect to be disappointed.
What are the Best stocks to invest in right now?
Check our buy/sell stock tips
Blog Categories
Get the Latest Insider Trades on ASX!
Recent Posts
Boss Energy (ASX:BOE) Production Downgrade, Rain-Driven Disruption, and Why FY27 Is Now the Test
Honeymoon guidance cut to 1.40-1.45M lbs as weather and infrastructure delays compound Boss Energy Limited’s (ASX:BOE) Honeymoon uranium operation in…
Nufarm (ASX:NUF) 17% EBITDA Jump, A$50m Cost Cut, and the De-leveraging Story Investors Missed
Net debt falls A$130m while a strategy reset quietly changes the earnings picture Nufarm Limited’s (ASX:NUF) first-half update landed this…
Immutep (ASX:IMM) wins FDA orphan status as efti Phase 2 hits 51.5% endpoint
Rebound gains fuel as FDA orphan tag backs 38-patient efti data Immutep (ASX:IMM) has received FDA orphan drug designation for…